ArticleExperimental and therapeutic medicine2025
Potential effects of liver dysfunction at the time of diagnosis in patients with acute myeloid leukemia.
Article in Experimental and therapeutic medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Liver involvement in pediatric acute leukemia: subtype differences and complex hepatic injury as a novel marker for AML risk stratification.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Whilst severe liver dysfunction is rarely encountered at the time of diagnosis for patients with acute myeloid leukemia (AML), mild elevations aminotransferase (<5 times the upper limit of normal) may be more frequently seen. Liver dysfunction at the time of diagnosis of AML is a parameter that requires investigation and can assist the clinicians in predicting prognosis. The aim of the present study was to investigate liver dysfunction at the time of diagnosis using the assoicated parameters in patients with AML. The present retrospective study included 90 patients diagnosed with AML who were hospitalised in the Hematology Clinic of Dışkapı Yıldırım Beyazıt Training and Research Hospital (Ankara, Turkey). The demographic characteristics of the patients were recorded together with hemogram results, anemia parameters, measurable residual disease positivity (MRD) and risk category, the presence of hepatosplenomegaly, infection, neutrophil recovery time (NRT), platelet recovery time (PRT) and liver dysfunction. The patients were analyzed in two groups following sorting into the liver dysfunction (n=45) and normal liver function test group (n=45). In the analysis of independent quantitative data (age, white blood cell count, hemoglobin, platelet, international normalized ratio, albumin, B12 vitamin, NRT, PRT) the Mann Whitney U-test was used. Independent qualitative data (sex, hepatomegaly, splenomegaly, MRD, risk category, infection) were analyzed using the χ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.